IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.
about
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker AssessmentInsulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant diseaseTargeting insulin and insulin-like growth factor signaling in breast cancerAn integrative genomic and transcriptomic analysis reveals potential targets associated with cell proliferation in uterine leiomyomasSymbolic data analysis to defy low signal-to-noise ratio in microarray data for breast cancer prognosis.Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.Integrative eQTL-based analyses reveal the biology of breast cancer risk lociCan we unlock the potential of IGF-1R inhibition in cancer therapy?The role of the insulin-like growth factor-1 system in breast cancerMicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiologyAn intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expressionLaser Capture Microdissection as a Tool to Study Tumor Stroma.Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.Insulin-like growth factor--phosphatidylinositol 3 kinase signaling in canine cortisol-secreting adrenocortical tumors.The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesisCixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
P2860
Q26798408-037077C8-913F-4431-8E37-F285EDD1C7F8Q26800001-4C0C1B57-8C6E-4CE5-884A-47E00A454D0AQ26826380-AE3F5E6C-F102-40FA-BDF4-200E74B4C2B6Q28487526-989D4766-999C-48D4-A79A-F9FB5C786796Q30658155-AE8F79AB-344C-4BD1-8636-2FD404E9F67EQ33866151-36ED777D-3717-4770-B40F-56F88C9A9037Q34194768-0C5CB54A-8C44-4BC2-BC4F-BB7BFC4C0E50Q34336988-2035CDE2-4A90-41D6-B6E1-83406EB4FB69Q35105295-CB8F7D0E-EC95-40CB-98D3-589AE529C2C6Q35140553-5BA0707C-4CE7-431A-82B5-4A11C62D4FA2Q35556972-7AFABA62-C1A8-4E5A-BAF7-99A6E825EC24Q35609517-EBC1C3D2-392B-49AC-8602-4DF75D75D194Q35690638-A6FB7762-27FA-4F7A-9938-323C47F1846BQ36073563-21FE716F-3897-4651-9EB0-A333D2B74B4CQ36118789-FBDD68D7-0EA4-42E6-BC50-1C4B5280C753Q36169793-A88EFCAE-2681-4A70-AAD1-9D8DE1478A3BQ36873574-F80FE761-662C-4A5F-8102-7C4F6F7859B9Q37529387-71D97658-9502-4CB9-89C5-C860EB6DFC1DQ37638139-66EA369F-9788-45C9-B3B0-8CF3AC873089
P2860
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@ast
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@en
type
label
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@ast
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@en
prefLabel
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@ast
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@en
P2093
P2860
P1476
IGFBP ratio confers resistance ...... poor outcome in breast tumors.
@en
P2093
Joan M Carboni
Kristina A Jacob
Marc A Becker
Marco M Gottardis
Paul Haluska
S John Weroha
Sean C Harrington
Sergio E Gonzalez
Xiaonan Hou
P2860
P304
P356
10.1158/1078-0432.CCR-11-1806
P407
P577
2012-01-27T00:00:00Z